Author: Lockwood, Eric R ; Nishikawa, Kiisa C ; Han, Zhixiu ; Rivera, Daniel J ; Tahir, Uzma ; Tester, John T ; Rice, Nicole A ; Covey, Kaitlyn L ; Huck, Thomas G ; Hessel, Anthony L

Powered ankle-foot prostheses assist users through plantarflexion during stance and dorsiflexion during swing. Provision of motor power permits faster preferred walking speeds than passive devices, but use of active motor power raises the issue of control. While several commercially available algorithms provide torque control for many intended activities and variations of terrain, control approaches typically exhibit no inherent adaptation. In contrast, muscles adapt instantaneously to changes in load without sensory feedback due to the intrinsic property that their stiffness changes with length and velocity. We previously developed a "winding filament" hypothesis (WFH) for muscle contraction that accounts for intrinsic muscle properties by incorporating the giant titin protein. The goals of this study were to develop a WFH-based control algorithm for a powered prosthesis and to test its robustness during level walking and stair ascent in a case study of two subjects with 4-5 years of experience using a powered prosthesis. In the WFH algorithm, ankle moments produced by virtual muscles are calculated based on muscle length and activation. Net ankle moment determines the current applied to the motor. Using this algorithm implemented in a BiOM T2 prosthesis, we tested subjects during level walking and stair ascent. During level walking at variable speeds, the WFH algorithm produced plantarflexion angles (range = -8 to -19°) and ankle moments (range = 1 to 1.5 Nm/kg) similar to those produced by the BiOM T2 stock controller and to people with no amputation. During stair ascent, the WFH algorithm produced plantarflexion angles (range -15 to -19°) that were similar to persons with no amputation and were ~5 times larger on average at 80 steps/min than those produced by the stock controller. This case study provides proof-of-concept that, by emulating muscle properties, the WFH algorithm provides robust, adaptive control of level walking at variable speed and stair ascent with minimal sensing and no change in parameters.

News (Medical) associated with BionX Medical Technologies, Inc.

02 Jun 2023

·www.prnewswire.com

Global Musculoskeletal Partnering Deals Report 2023: Comprehensive Access to 600+ Available Deals and Contract Documents

DUBLIN, June 2, 2023 /PRNewswire/ -- The "Global Musculoskeletal Partnering 2016-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. This report provides the full collection of musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2016. Trends in musculoskeletal partnering deals Financial deal terms for headline, upfront and royalty by stage of development Musculoskeletal partnering agreement structure Musculoskeletal partnering contract documents Top musculoskeletal deals by value Most active musculoskeletal dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering musculoskeletal deals. The report presents financial deal terms values for musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Report scope The report is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide. Global Musculoskeletal Partnering 2016 to 2023 includes: Trends in musculoskeletal dealmaking in the biopharma industry since 2016 Access to headline, upfront, milestone and royalty data Access to hundreds of musculoskeletal deal contract documents Comprehensive access to over 600 musculoskeletal deal records The leading musculoskeletal deals by value since 2016 Most active musculoskeletal dealmakers since 2016 The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthritis, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications. In Global Musculoskeletal Partnering 2016 to 2023, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Musculoskeletal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are the sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in musculoskeletal dealmaking 2.1. Introduction 2.2. Musculoskeletal partnering over the years 2.3. Musculoskeletal partnering by deal type 2.4. Musculoskeletal partnering by industry sector 2.5. Musculoskeletal partnering by stage of development 2.6. Musculoskeletal partnering by technology type 2.7. Musculoskeletal partnering by therapeutic indication Chapter 3 -Financial deal terms for musculoskeletal partnering 3.1. Introduction 3.2. Disclosed financials terms for musculoskeletal partnering 3.3. Musculoskeletal partnering headline values 3.4. Musculoskeletal deal upfront payments 3.5. Musculoskeletal deal milestone payments 3.6. Musculoskeletal royalty rates Chapter 4 - Leading musculoskeletal deals and dealmakers 4.1. Introduction 4.2. Most active in musculoskeletal partnering 4.3. List of most active dealmakers in musculoskeletal 4.4. Top musculoskeletal deals by value Chapter 5 - Musculoskeletal contract document directory 5.1. Introduction 5.2. Musculoskeletal partnering deals where contract document available Chapter 6 - Musculoskeletal dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by musculoskeletal therapeutic target Companies Mentioned 3D-Side 3SBio A2A Pharmaceuticals Aavis Pharmaceuticals Abarca Abbvie AbCellera AC Bioscience Accenture Actigraph Activbody Active Implants Adaptive Health Additive Orthopaedics Advanced Human Imaging AdventHealth Affinia Therapeutics AGC Asahi Glass AgNovos Healthcare AgomAb Therapeutics Akashi Therapeutics AKL Research and Development AlfaMed Aligos Therapeutics AliMed Alkem Laboratories Allergan AlloSource Almirall Alpine Immune Sciences Altamira Bio Altasciences Alvogen Alvotech Ambry Genetics Amedica Amend Surgical American Association of Neuromuscular & Electrodiagnostic Medicine Amgen Amneal Pharmaceuticals AMRA AMRA Medical Anagenesis Biotechnologies Analysis Group AnaMar Angelini Pharma Angers University Anika Therapeutics ANI Pharmaceuticals Antares Pharma Antibe Therapeutics Apexigen Apple Apsen Farmacutica Aptahem Aptorum Group Aralez Pharmaceuticals Aratana Therapeutics Aravive Biologics argenx ARK Crystal Arrowhead Pharmaceuticals Arthrex Arthrosi Therapeutics Artialis Asahi Kasei Ascendis Pharma AskAt Asklepios Biopharmaceutical Assertio Therapeutics Astellas Pharma AstraZeneca Athrotech Atnahs Pharma Audentes Therapeutics Aurinia Pharmaceuticals Australian Research Council Autotelic BIO Avalere Health Avanos Medical Aveta Biomics AveXis Avidity Biosciences Avion Pharmaceuticals AWB Schraubtechnik und Industriebedarf Axovant Gene Therapies Azellon Cell Therapeutics Aziyo Biologics Back-A-Line Bacterin International Baebies Bamboo Therapeutics Bauerfeind Baxalta Bayer Baylor College of Medicine Bazis NN BC Platforms Beijing Tide Pharmaceutical Benitec Biopharma Berg BGI BillionToOne Bio-Thera Solutions BioAge Labs BioCanRx Biocomposites Biogen BioGen Medical Biohaven Pharmaceuticals BioInvent BioMarin Pharmaceutical BioMed X Innovation Center BionX Medical Technologies BioPharma Forest Bioqube Ventures Bioservo Technologies Biosolution Biosplice Bioventus BioVinc Bison & Rose Blue Belt Technologies Blueprint Medicines Bodycad Boehringer Ingelheim Bone Biologics Bone Therapeutics Brickell Biotech Brigham and Women's Hospital Bristol-Myers Squibb BRM Extremities BSN Medical Burke Therapeutics c-LEcta California Institute for Biomedical Research California Institute for Regenerative Medicine Calimmune Calliditas Therapeutics Camargo Pharmaceutical Services Camber Spine Technologies Can-Fite BioPharma CANbridge Pharmaceuticals Cantargia Capricor Therapeutics Capsigen CareFirst BlueCross BlueShield Carlsmed Carna BioSciences CartiHeal Cartiva CAS Casper Pharma Catabasis Pharmaceuticals Catalyst Pharmaceuticals cbdMD Cedars-Sinai Medical Center Celgene Celltech Cellthera Pharma Cell Therapy Catapult Celltrion Cellular Biomedicine Cel Sci Centinel Spine Centogene Cerhum For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Cell Therapy

19 Aug 2022

·www.prnewswire.com

Microbiome Partnering Worldwide, 2010 to 2022 - Dealmaking Trends by the World's Leading Healthcare Companies in the Biopharma Industry Since 2010

DUBLIN, Aug. 19, 2022 /PRNewswire/ -- The "Global Microbiome Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering. The Global Microbiome Partnering Terms and Agreements 2010 to 2022 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Microbiome dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to over 250 Microbiome deal records and contract documents where available The leading antibody deals by value since 2010 Most active Microbiome dealmakers since 2010 The leading Microbiome partnering resources The Global Microbiome Partnering Terms and Agreements report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Microbiome partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Microbiome technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains links to online copies of actual Microbiome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of Microbiome dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Microbiome dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading Microbiome deals since 2010. Deals are listed by headline value, signed by big pharma, most active Microbiome dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in Microbiome dealmaking with a brief summary followed by a comprehensive listing of Microbiome deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of Microbiome partnering deals signed and announced since Jan 2010. The chapter is organized by specific Microbiome technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by Microbiome partnering company A-Z, deal type definitions and Microbiome partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Microbiome partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Microbiome technologies and products. Companies Mentioned 4D Pharma 9 Meters Biopharma Aarhus University Abbott Laboratories Abbvie ADL Bionatur Solutions ADM AIDS Clinical Trials Group Alimentary Health Allergan ALS Association Amag Pharmaceuticals American Type Culture Collection (ATCC) Ancilia Biosciences AnimalBiome AntibioTx Arc Bio Archer Daniels Midland Company Arena Pharmaceuticals Argonne National Laboratory Ariana Pharma Arranta Bio Artizan Biosciences Assembly Biosciences AstraZeneca Aurealis Therapeutics Azitra BASF Bayer Bayer CropScience Bayer Healthcare Baylor College of Medicine Baylor Miraca Genetics Laboratories Beam Therapeutics Bertin Pharma Bill and Melinda Gates Foundation Bio-Me Bio-Rad Laboratories BIOASTER Biocodex Microbiota Foundation Biocogent Biocore Biofortis Biohaven Pharmaceuticals BiomeBank Biomecite Diagnostics Biomedical Advanced Research and Development Authority Biomica Biomillenia Biomodels BiomX BionX Medical Technologies Bio Palette Biosortia Pharmaceuticals Bloom Science Boehringer Ingelheim Boston University School of Medicine Brigham and Women's Hospital Bristol-Myers Squibb Brown University Cancer Research UK CARB-X Carbiotix Cargill Cedars-Sinai Medical Center Centers for Disease Control and Prevention Centre Leon Berard Centre National de la Recherche Scientifique Centro Sperimentale del Latte Children's Hospital Boston Circuit Clinical Clalit Health Services and many, many more! For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Antibody

14 Jun 2022

·www.biospace.com

Bionics Market Trend- Rapid Advancements in Bionics Technology

Increasing incidence of disabilities and organ failures, rising cases of road accidents and trauma cases, and increasing prevalence of chronic conditions leading to amputation are some key factors expected to drive global Bionics market growth. Market Dynamics: Bionics also called biologically inspired engineering is application of biological systems found in nature for studying and designing engineering systems and modern technology. Bionics aids in development of artificial organs and body parts. Bionic implants are widely gaining traction owing to increasing prevalence of age-related disorders and irreversible physical injuries, and rising availability of advanced bioimplants for various organs. Factors such as increasing awareness about the benefits of organ transplants and rising investments by private and public organizations for research and development activities are expected to drive global market revenue growth during the forecast period. Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ However, high costs of bionics devices, lack of favorable reimbursement scenarios, and insufficient funds in many developing and underdeveloped economies are some key factors that can hamper overall market growth to a certain extent during the forecast period. COVID-19 Impact Analysis Social distancing and restrictions severely disrupted businesses and operations Lockdowns caused disruptions in transportation and logistics Impacted manufacturing activities and mining operations globally Took a toll on economy of various countries Caused sudden and drastic downturn in economic activity Disrupted agriculture, fisheries, dairy, and other sectors Caused loss of employment and financial crisis Supply impacts were further compounded owing to reduced disposable income Emergence of variants continue to cause concerns and impact normal routines Ear Bionics Segment to Account for Significantly Larger Revenue Share: The ear bionics segment is expected to account for significantly larger revenue share between 2020 and 2028 owing to increasing incidence of hearing disorders, rising geriatric population, increasing number of ear surgeries, and high demand for advanced cochlear implants, auditory brainstem implants, and anchored hearing systems. Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ Implantable Bionics Segment To Register Rapid Revenue CAGR: The implantable bionics segment is expected to register rapid revenue CAGR over the forecast period owing to factors such as increasing number of road accidents and traumatic amputations, growing preference for bioimplants, rising healthcare expenditure, and growing preference for bioimplants over external bionics. North America to Lead In Terms of Revenue Share: North America is expected to dominate other regional markets in terms of revenue share during the forecast period owing to rising prevalence of road accidents and physical injuries, increasing incidence of amputation due to chronic conditions, rapid advancements in bionic technology, and presence of well-developed healthcare infrastructure. In addition, rising availability of bionic products for various organs, high per capita income, and increasing investments in developing advanced products are expected to fuel North America market growth during the forecast period. Major Companies in the Market Include: Medtronic Plc Abbott Laboratories Biomet, Inc. Zimmer Biomet Iwalk, Inc. ABIOMED, INC Berlin Heart GmBH Ekso Bionics Boston Scientific Corporation Edward Lifesciences Corporation Jarvik Heart, Inc. Heartware International, Inc. SynCardia Systems, LLC Browse Full Report Description + Research Methodology + Table of Content + Infographics@ For the purpose of this report, Emergen Research has segmented the global bionics market based on product type, method of fixation, technology, and region: Product Type Outlook ((Revenue, USD Billion; 2017–2027) Ear Bionics Cochlear Implants Auditory Brainstem Implants Bone Anchored Hearing Systems Vision Bionics Orthopedic Bionics Upper limb Lower limb Exoskeleton Electrical Bone Growth Stimulators Cardiac Bionics Total Artificial Heart Pacemaker Ventricular Assist Device Biventricular Assist Device (BIVAD) Left Ventricular Assist Device (LVAD) Right Ventricular Assist Device (RVAD) Artificial Heart Valves Neural/Brain Bionics Internal Neurostimulators Deep Brain Stimulators (DBS) Spinal Cord Stimulators (SCS) Vagus Nerve Stimulators (VNS) Sacral Nerve Stimulators (SNS) Others Method of Fixation Outlook (Revenue, USD Billion; 2017–2027) External Bionics Implantable Bionics Technology Outlook (Revenue, USD Billion; 2017–2027) Mechanical Electronic Regional Outlook (Revenue, USD Billion; 2017–2027) North America U.S. Canada Mexico Europe Germany France U.K. BENELUX Italy Rest of Europe Asia Pacific China India Japan South Korea Rest of APAC Latin America Brazil Rest of LATAM Middle East & Africa Saudi Arabia U.A.E. South Africa Turkey Rest of MEA Looking to Purchase Reports in Bundle [Schedule a Call with An Analyst]@ Read our Publication on different Websites: Emergen Research ello Account Emergen Research openstreetmap Account Emergen Research crieit Account Emergen Research tananet Account Emergen Research twitch.tv Account Emergen Research patreon Account Emergen Research etsy Account Emergen Research w3.org Account Emergen Research flickr Account Emergen Research bandcamp Account Emergen Research vimeo Account About Emergen Research Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors. Contact Us: Eric Lee Corporate Sales Specialist Emergen Research | Web: Direct Line: +1 (604) 757-9756 E-mail: sales@emergenresearch.com Visit for More Insights: Explore Our Custom Intelligence services | Growth Consulting Services

100 Deals associated with BionX Medical Technologies, Inc.

100 Translational Medicine associated with BionX Medical Technologies, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BIO-017 ( TRPV1 )	Angelman Syndrome More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis